GSK plc
London Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- GSK plc operates as a global biopharmaceutical leader, dedicated to the research, development, and delivery of innovative medicines and vaccines across international markets. The company, which traces its origins back to 1715, refocused its strategy in July 2022 by spinning off its Consumer Healthcare division to form Haleon plc, thereby concentrating exclusively on its biopharma pipeline. Its operations are structured around key product areas: Specialty Medicines, Vaccines, and General Medicines. Within Specialty Medicines, GSK develops treatments for significant health challenges including HIV, oncology, respiratory conditions, and immuno-inflammatory diseases such as lupus. The Vaccines portfolio encompasses a broad range, preventing illnesses like shingles (Shingrix), meningitis, and respiratory syncytial virus (RSV) with its Arexvy vaccine. General Medicines typically address primary care needs, including inhalers for asthma and COPD, and various antibiotics. GSK generates revenue through the sale of these prescription products and vaccines to healthcare providers, hospitals, pharmacies, and governmental bodies worldwide. The company is strategically prioritizing investment in its innovative pipeline, anticipating at least twelve major product launches from 2025 in areas like infectious diseases, HIV, oncology, and respiratory health, reinforcing its commitment to scientific advancement. Recent corporate activities include strategic acquisitions such as Tesaro to bolster its oncology presence, and alliances with partners like CureVac for mRNA vaccine development. Headquartered in Brentford, United Kingdom, GSK aims to positively impact the health of 2.5 billion people by the end of the decade, driven by its purpose to unite science, technology, and talent to get ahead of disease. The company was formerly known as GlaxoSmithKline plc and adopted its current name, GSK plc, in May 2022.
Thistle Resources intersects broad gold mineralization at Middle River
Snail Games brings Bellwright to PlayStation and Xbox as console push advances
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Abacus Global Management launches AI lifespan modeling platform
GSK falls as £8bn takeover of Nuvalent is largest deal in a decade
Longspur initiates on Gelion with 153p target, saying its battery tech can undercut China
US bank sees GSK oncology pipeline as major value driver after New York conference
Gunnison Copper targets resource expansion with new district-wide drill program at flagship Arizona project
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading
Sonoro Gold upsizes private placement to C$15M amid investor demand
JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited
Ideal Power to host Q1 2026 earnings conference call on May 14
OTC Markets Group adds Charlotte’s Web to OTCQX Best Market
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio
88 Energy and Burgundy amend Phoenix arrangements
Bango targets positive cash earnings from subscriptions division in 2027 after strong start to year
GSK sells rights to rare liver disease drug for up to $690m
GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments
Citi lifts GSK target price but keeps neutral stance after rally
ShoreCap says GSK has cracked it and the £40bn prize is now in sight